Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localised radiotherapy.

[1]  J. Becker,et al.  Expression of stress-induced MHC class I related chain molecules on human melanoma. , 2002, The Journal of investigative dermatology.

[2]  D. Kabelitz,et al.  Activation of V gamma 9V delta 2 T cells by NKG2D. , 2005, Journal of immunology.

[3]  L. Platanias,et al.  Statins in tumor suppression. , 2008, Cancer letters.

[4]  C. Hollenbeak,et al.  Increased incidence of melanoma in renal transplantation recipients , 2005, Cancer.

[5]  K. Kölmel,et al.  Spontaneous Regression of Advanced Malignant Melanoma , 1998, Oncology Research and Treatment.

[6]  A. Hayday.  [gamma][delta] cells: a right time and a right place for a conserved third way of protection. , 2000, Annual review of immunology.

[7]  C. Brosnan,et al.  IL-12-Mediated NKRP1A Up-Regulation and Consequent Enhancement of Endothelial Transmigration of Vδ2+ TCRγδ+ T Lymphocytes from Healthy Donors and Multiple Sclerosis Patients , 1999, The Journal of Immunology.

[8]  S. Chouaib,et al.  Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. , 2005, Journal of immunology.

[9]  P. Reimer,et al.  Gammadelta T cells for immune therapy of patients with lymphoid malignancies. , 2003, Blood.

[10]  A. Conney,et al.  Atorvastatin and Celecoxib Inhibit Prostate PC-3 Tumors in Immunodeficient Mice , 2007, Clinical Cancer Research.

[11]  C. Montesano,et al.  Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo , 2003 .

[12]  A. Anichini,et al.  Immunotherapy of melanoma. , 2003, Seminars in cancer biology.

[13]  P. Clézardin,et al.  Mechanisms of Bisphosphonate Effects on Osteoclasts, Tumor Cell Growth, and Metastasis , 2002, American journal of clinical oncology.

[14]  M. Eberl,et al.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. , 2007, Cancer research.

[15]  D. Kabelitz,et al.  Activation of Vγ9Vδ2 T Cells by NKG2D1 , 2005, The Journal of Immunology.

[16]  M. Bonneville,et al.  Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. , 1994, Science.

[17]  J. Kirkwood,et al.  Focus on FOCIS: interleukin 2 treatment associated autoimmunity. , 2008, Clinical immunology.

[18]  C. Langford,et al.  Distinct Cytokine-Driven Responses of Activated Blood γδ T Cells: Insights into Unconventional T Cell Pleiotropy1 , 2007, The Journal of Immunology.

[19]  D. Kabelitz,et al.  Perspectives of gammadelta T cells in tumor immunology. , 2007, Cancer research.

[20]  P. Pisa,et al.  Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages , 2008, Cancer Immunology, Immunotherapy.

[21]  Y. Tanaka,et al.  Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. , 1995, Nature.

[22]  G. De Libero,et al.  Human T Cell Receptor γδ Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells , 2003, The Journal of experimental medicine.

[23]  Yoshimasa Tanaka,et al.  Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study , 2007, Cancer Immunology, Immunotherapy.

[24]  V. Sondak,et al.  Complete Spontaneous Regression of Pulmonary Metastatic Melanoma , 1998, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[25]  M. Bonneville,et al.  Sensing cell stress and transformation through Vγ9Vδ2 T cell-mediated recognition of the isoprenoid pathway metabolites , 2005 .

[26]  Hong Wang,et al.  Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens , 2007, Immunological reviews.

[27]  M. Mason,et al.  Systemic treatments for metastatic cutaneous melanoma. , 2000, The Cochrane database of systematic reviews.

[28]  S. Chouaib,et al.  Phosphostim-Activated γδ T Cells Kill Autologous Metastatic Renal Cell Carcinoma1 , 2005, The Journal of Immunology.

[29]  G. Keren,et al.  The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. , 2008, Atherosclerosis.

[30]  M. Rogers,et al.  Molecular Mechanisms of Action of Bisphosphonates: Current Status , 2006, Clinical Cancer Research.

[31]  F. Nestle,et al.  Vaccines and melanoma , 2002, Clinical and experimental dermatology.

[32]  M. Zöller,et al.  Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. , 2004, Journal of immunology.

[33]  L. Nan,et al.  EX VIVO EXPANDED HUMAN Vλ9Vδ2+ λδ-T CELLS MEDIATE INNATE ANTITUMOR ACTIVITY AGAINST HUMAN PROSTATE CANCER CELLS IN VITRO , 2005 .

[34]  Y. Herouy.  Lipodermatosclerosis and compression stockings. , 2000, Journal of the American Academy of Dermatology.

[35]  M. Zöller,et al.  Characterization of Tumor Reactivity of Human Vγ9Vδ2 γδ T Cells In Vitro and in SCID Mice In Vivo1 , 2004, The Journal of Immunology.

[36]  L. Lanier,et al.  Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family , 2001, Immunogenetics.

[37]  J. Kirkwood,et al.  Next generation of immunotherapy for melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Z. Werb,et al.  Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. , 2007, Cancer research.

[39]  T. Sayers,et al.  TNF‐related apoptosis‐inducing ligand as a therapeutic agent in autoimmunity and cancer , 2006, Immunology and cell biology.

[40]  Stewart Fw.  Experiences in spontaneous regression of neoplastic disease in man. , 1952 .

[41]  B. Bloom,et al.  Natural and synthetic non-peptide antigens recognized by human γδ T cells , 1995, Nature.

[42]  M. Bonneville,et al.  Sensing cell stress and transformation through Vgamma9Vdelta2 T cell-mediated recognition of the isoprenoid pathway metabolites. , 2005, Microbes and infection.

[43]  Nathanson.  Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms. , 1976, National Cancer Institute monograph.

[44]  M. Büchler,et al.  Zoledronic Acid has Direct Antiproliferative and Antimetastatic Effect on Pancreatic Carcinoma Cells and Acts as an Antigen for δ2 γ/δ T Cells , 2007, Journal of immunotherapy.

[45]  Masahiro Inoue,et al.  An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. , 2004, The Journal of clinical investigation.

[46]  Natale Cascinelli,et al.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.

[47]  L. Zitvogel,et al.  The anticancer immune response: indispensable for therapeutic success? , 2008, The Journal of clinical investigation.

[48]  D. Nowis,et al.  Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. , 2007, International journal of oncology.

[49]  C. Montesano,et al.  Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. , 2003, Blood.

[50]  L. Nan,et al.  Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro. , 2005, The Journal of urology.

[51]  C. Brosnan,et al.  IL-12-mediated NKRP1A up-regulation and consequent enhancement of endothelial transmigration of V delta 2+ TCR gamma delta+ T lymphocytes from healthy donors and multiple sclerosis patients. , 1999, Journal of immunology.

[52]  C. N. Coleman,et al.  External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing , 2004, Cancer Research.

[53]  P Jensen,et al.  Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. , 1999, Journal of the American Academy of Dermatology.